fbpx Yourgene Health plc - Home
DSC00185r.jpg
002-news.jpg
003-news.jpg
001-news.jpg
004-news.jpg
previous arrow
next arrow

Last week we had the great news that a safe and effective vaccine against SARS-CoV-2 should soon be available. Thanks to the work of Pfizer and BioNTech, we may have the opportunity to start vaccinating those at highest risk of severe disease towards the end of this year and into 2021. The interim analysis of their clinical trial has indicated that it is more than 90% effective in preventing COVID-19 in participants who haven’t been infected with SARS-CoV-2 previously, when participants received 2 doses of the vaccine 21 days apart. The trial continues and there remains much that is still unknown – how long will immunity last?Will it offer effective in those who have had prior exposure to SARS-CoV-2? And will it help reduce the transmissibility for those vaccinated, a vital element in reaching indirect protection (or herd immunity) through vaccination1

Vaccination is an important part of what will be required for this countryand the world,to move past a series of lockdowns and travel bans, but it is just one part of what is required. Testing and isolating those individuals who are infectious with SARS-COV-2 to minimise transmission, as well as treatments for severe disease and long-COVID will also be required for those who still contract COVID-19. We are now fortunate to have a variety of sensitive and specific PCR based tests availablethat can detect if you currently have a SARS-CoV-2 infection. Gold standard PCR based testing, alongside the new rapid antigen and antibody tests which are proving to be less accurate2 but important because of their ability to give a rapid result, are a powerful toolbox to determine who is infected and who has previously been infected. There are many clinical trials investigating treatments for COVID-19 ongoing across the globe. Most treatments currently in trials are either antivirals to prevent the virus from multiplying, or immune modulators which help the immune system to create a response against SARS-COV-2 or prevent the immune system from dangerously overreacting against the virus. In the UK, the RECOVERY trial3 is currently testing low dose dexamethasone for use in children, Azithromycin (a commonly used antibiotic), Tocilizumab (an anti-inflammatory treatment), convalescent plasma (containing antibodies from donors who have recovered from COVID-19), REGN-COV2 (monoclonal antibodies directed against coronavirus) and Aspirin (used as an anticoagulant to thin the blood). Just last weekend, the NHS announced the start of 40 specialist long-COVID clinics to help the 60,000 individuals who have been left with longterm fatigue, breathlessness and pain as a result of SARS-CoV-2 infection. 

With so many rapid advancements that the medical and scientific communities have provided to address the challenges that SARS-COV-2 has bought this year; we have much to be optimistic about longer term. It is important that we still recognise that it will take time to vaccinate the population and find the best treatments for those affected. The government has purchased 40 million doses of the Pfizer/BioNTech vaccineenough to vaccinate 20 million people using the 2-dose regime. It is hoped that the first 10 million doses may be delivered this year but it takes 28 days after the first dose to be effective in 9 out of 10 cases, and even 40 million doses will be sufficient forjust under 30% of the 67 million population. With 25% of the UK’s population being classified as highly vulnerable, it is only correct that they will be prioritised for vaccination, but this will leave the large majority of the population at risk for the foreseeable future and especially through these next few crucial winter months.

We look forward to the day when we will be able to return to meeting our customers face to face, meet our colleagues again in person, and being with our family and friends once more, but until then we are looking after our team by offering staff and family COVID testing with our Clarigene® SARS-CoV-2 test in our own genomic services laboratory. We will continue to support our partners to return safely back to work through our workplace testing – which is available through MediskillsReCoVaand Caxtonamongst others. And for our own technical support team, testing services have been important to allow them to resume travelling to existing and new customer sites rolling out the new IONA®Nx NIPT test to sites across Europe and beyond. 

1. Paul Fine, Ken Eames and David Haymann. CID 2020, 52 (7): 911-916. DOI: 10.1093/cid/cir007

2. RanyeMulchandani et al. BMJ 2020; 371: m4262. DOI: https://doi.org/10/1136/bmj.m4262

3. www.recoverytrial.net

  • New Year, New Regulations - 19 January 2022 +

    The ‘New Year's resolution’ is a tradition almost all of us are familiar with, in which a person resolves to accomplish a personal goal, continue good habits or change undesirable ones all with the intention of self-improvement. A study of over 800 million activity data points on the exercise platform Strava found that today, January 19th, is the most common day for a New Year’s resolution to be abandoned ( 1 ). If you are reading this

    Read More
  • Behind the scenes: Adapting diagnostic services during a pandemic - 11 November 2021 +

    The diagnostic testing business has always been dynamic and opportunistic , but nothing could have stretched the definition of these 2 words like a pandemic.

    Since the launch of Yourgene Genomic Services 6 months into this global pandemic – born from a legacy, well established NIPT service laboratory, a modest acquisition, and an unprecedented national genomic testing demand, we have vastly expanded our testing capacity by converting every spare inch of underutilised office space created by remote

    Read More
  • Overprescribing within the NHS - 02 November 2021 +

    “Good for you, good for us but is it good for everybody?”
    Overprescribing within the NHS – October 2021


    The NHS is currently the 5th largest global employer; with over 1.3m employees and receiving around 10% of the UK Government’s annual spending. It is estimated that the NHS deals with 336 million ‘patient visits’ per year, - many of whom will receive some form of at least one ‘prescription’ per visit and at a current charge in

    Read More
  • The role genomics plays in relationships - 18 August 2021 +

    According to National Today, the website dedicated to highlighting every day celebrations and holidays, August 18 th is ‘National Couple’s Day’ – a day to celebrate the important relationships in life. Whilst not an official holiday or observance in any country, the clinical team at Yourgene Health wanted to use this opportunity to reflect upon the pivotal role that genomics plays in relationships across the world.

    Earlier this year a study, published in Nature Human Behaviour,

    Read More
  • NIPT for Sex Chromosome Aneuploidies and Autosomal Aneuploidies. A Q&A with Dr Greg Fitzgibbon - 26 May 2021 +

    Yourgene Health has recently launched IONA ® Care , an advanced prenatal screening test that performs whole-genome analysis to measure the likelihood that a pregnant woman is carrying a fetus with one the most common trisomies (trisomy 21, 18 and 13), any other Autosomal Aneuploidy (AA) or a Sex Chromosome Aneuploidy (SCA). IONA ® Care is available from the Yourgene Genomic Services laboratory in Manchester, UK. The test is available as a menu, enabling pregnant women, their families

    Read More
  • COVID-19 testing and the need for regulation - 6 May 2021 +

    The COVID-19 pandemic presented huge challenges worldwide. In response to the unprecedented need for COVID-19 PCR testing, the UK government set up a new network of Lighthouse laboratories across the country to provide the required capacity for testing thousands of samples each day. These laboratories proved a vital part of the test and trace strategy but were also under immense pressure to meet their targets and, following an investigation by Panorama , it was found that

    Read More
  • Yourgene on World Creativity and Innovation Day 2021 - 21 April 2021 +

    Innovation and creativity are two pillars at the heart of technological and scientific advances. The instrumental role they play has been recognised by the United Nations (UNN), who have designated a special day to raise awareness of the importance of innovation in culture and economic growth worldwide: 21st April. World Creativity and Innovation Day (UNN) is a day to encourage people to “think outside the box”, find new perspectives which push personal growth, identify different

    Read More
  • The IONA® test recommended for twin pregnancies screening for Down’s syndrome - 7 April 2021 +

    In recent years, fertility treatments and the fact women are having babies later has made multiple births more common. In 2016, around 12,000 sets of twins and about 190 sets of triplets or more were born in the UK. That means about 1 in every 65 births in the UK today are twins, triplets or more. 1 Extensive studies have been carried out for cell-free DNA (cfDNA) testing in singleton pregnancies with sample numbers into

    Read More
  • Blood clots, inherited thrombophilia and COVID-19 - 25 March 2021 +

    Recent reports in the media from a collection of European countries suggest that there may be cause for concern with regards to the Oxford AstraZeneca COVID-19 vaccine and abnormal blood clotting. According to Norway’s medicines agency (NoMA), four new cases of “serious blood clotting in adults” have been identified following a recent review (1). Austria have suspended the use of one particular batch of the vaccine after two events, including an individual diagnosed with multiple

    Read More
  • COVID-19 strains - what are they and why do they matter? A Q&A with Dr Michael Risley - 28 January 2021 +

    The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. In recent months we have seen the rollout of ambitious vaccination schedules worldwide, as well as the strengthening of

    Read More
  • So much to be proud of! - 23 December 2020 +

    As many have already said and written, this year has been like none other. This has been especially true for conferences and exhibitions. Every year, the commercial team at Yourgene look forward to exhibiting at various conferences globally. It’s a chance to meet our partners and customers, as well as form new relationships. With the COVID-19 pandemic none of this was possible, so when we heard that the Taiwan Healthcare Expo was still going ahead,

    Read More
  • COVID-19 vaccines and the continued role of testing - 16 November 2020 +

    Last week we had the great news that a safe and effective vaccine against SARS-CoV-2 should soon be available. Thanks to the work of Pfizer and  BioNTech , we may have the opportunity to start vaccinating those at highest risk of severe disease towards the end of this year  and into 2021.  The interim analysis of their clinical trial has indicated that it is more than 90% effective in preventing COVID - 19 in participants who haven’t

    Read More
  • The role of DPYD testing in managing a successful response to the COVID-19 pandemic - 5 November 2020 +

    Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. Two key pillars in the fight against the pandemic are establishing a robust testing strategy and implementing procedures and processes to reduce the burden on healthcare systems.  

    Independent SAGE recently published a document containing core recommendations for how best to optimize and develop the current testing

    Read More
  • 1